Honokiol

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Honokiol
Category Others
Catalog number BBF-03868
CAS 35354-74-6
Molecular Weight 541.6
Molecular Formula C34H31N5O2
Purity ≥98%

Ordering Information

Catalog Number Size Price Stock Quantity
BBF-03868 50 g $457 In stock

Online Inquiry

Add to cart

Description

Honokiol is a polyphenol found in the genus Magnolia. Honokiol acts as an Akt inhibitor and also inhibits NF-κB, displaying anti-inflammatory, antiangiogenic and antitumor properties. It results in inhibition of bone metastatic growth of human prostate cancer cells. Honokiol has obvious antioxidant and anti-aging effects, thus can be used in cosmetic material. It is a plant polyphenol that can inhibit tyrosinase, block melanin synthesis, reduce skin pigment intensity, absorb UV, prevent photoaging, reduce sun damage and age spot formation, and whiten and lighten spots. It also has the anti-glycation effect, can effectively improve skin tone and skin texture, prevent the generation of age spots, remove red bloodlines, and improve skin blood microcirculation. It has the activity of antibacterial, anti-inflammatory, antioxidant, oil control, acne, promoting healing, and can be widely used in anti-acne, deodorization, acne and other products.

Specification

Synonyms Honokiol;35354-74-6;5,3'-Diallyl-2,4'-dihydroxybiphenyl;NSC 293100;3,5'-Diallyl-4,2'-dihydroxybiphenyl;3',5-Diallylbiphenyl-2,4'-diol;C18H18O2;3',5-diallyl-2,4'-biphenyldiol;CPD000387107;CHEMBL16901;2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol;CHEBI:5759;4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol;11513CCO0N;2-[4-hydroxy-3-(prop-2-en-1-yl)phenyl]-4-(prop-2-en-1-yl)phenol;5,3'-Diallyl-biphenyl-2,4'-diol;MFCD00016674;NSC293100;[1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-;3',5-Di-2-propen-1-yl[1,1'-biphenyl]-2,4'-diol;NSC-293100;Honokiol,(S);2-(4-hydroxy-3-prop-2-enyl-phenyl)- 4-prop-2-enyl-phenol;(1P)-3',5-di(prop-2-en-1-yl)[1,1'-biphenyl]-2,4'-diol;3',5-(5,5'-)Diallyl-[1,1'-biphenyl]-2,4'-(2,2'-)diol;SMR000387107;3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol;Purinol;(1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPENYL-;UNII-11513CCO0N;Honokiol?;-dihydroxydiphenyl;3',5-diallyl-[1,1'-biphenyl]-2,4'-diol;Honokiol, HO;3',5-Di-2-propen-1-yl-[1,1'-biphenyl]-2,4'-diol; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl- (9CI); 3',5-Diallyl-2,4'-biphenyldiol; Honokiol; NSC 293100;5,3′Honokiol - 95%;-Diallyl-2,4′FMLT BSASM H;HONOKIOL [MI];HONOKIOL [WHO-DD];Honokiol, analytical standard;cid_72303;MLS000759481;MLS001048916;MLS001423980;MLS006011755;SCHEMBL133034;REGID_for_CID_72303;GTPL11610;DTXSID30188845;3',1'-biphenyl)-2,4'-diol;HMS2051C12;HMS2271J07;HMS3393C12;HMS3656G03;(1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPEN-1-YL-;AMY40657;BCP28282;HY-N0003;AC-486;BBL027819;BDBM50157304;HB0328;s2310;STK801954;3'',5-diallylbiphenyl-2,4''-diol;Honokiol, >=98% (HPLC), powder;3,5'-diallyl-2',4-dihydroxybiphenyl;AKOS005622639;3',5-Diallyl-2,4'-dihydroxybiphenyl;CCG-100864;CS-1696;NC00114;5,3''-Diallyl-biphenyl-2,4''-diol;SMP2_000040;NCGC00163567-01;NCGC00163567-02;NCGC00163567-03;NCGC00163567-08;AS-15333;XH163752;5,3''''-Diallyl-biphenyl-2,4''''-diol;H1309;NS00011726;SW197494-3;EN300-7399522;A822747;SR-01000758208;Q-100425;Q5896650;SR-01000758208-5;{1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-;3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol;BRD-K98493452-001-01-6;BRD-K98493452-001-14-9;Honokiol, European Pharmacopoeia (EP) Reference Standard;Z2065671480;[1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl;4-[2-hydroxy-5-(prop-2-en-1-yl)phenyl]-2-(prop-2-en-1-yl)phenol;InChI=1/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H;N-[[4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]methyl]-2-fluoroaniline; N-?(2-?Fluorophenyl)?-?5-?(6-?methyl-?2-?pyridinyl)?-?4-?[1,?2,?4]?triazolo[1,?5-?a]?pyridin-?6-?yl-1H-?imidazole-?2-?methanamine;Y4T;
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
IUPAC Name 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
Canonical SMILES C[C@@H](C1=CC2=CC=CC=C2C=C1)NC(=O)C3=C4C(=CC=C3)N=C(N4CCCC(=O)NC)C5=CN=CC6=CC=CC=C65
InChI InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
InChI Key FVYXIJYOAGAUQK-UHFFFAOYSA-N

Properties

Appearance White Solid
Application anti-inflammatory and anti-cancer agent
Antibiotic Activity Spectrum Gram-positive bacteria; neoplastics (Tumor)
Boiling Point 400.1°C at 760 mmHg
Melting Point 80-85°C
Flash Point 184°C
Density 1.107 g/cm3
Solubility Soluble in DMSO (36 mg/mL)

Reference Reading

1.Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity.
Das S1, Stark L2, Musgrave IF1, Pukala T3, Smid SD1. Food Funct. 2016 Feb 17;7(2):1138-46. doi: 10.1039/c5fo01281c.
In this study we compared the effects of a diverse set of natural polyphenolics ligands on in silico interactive modelling, in vitro anti-aggregative properties and neuronal toxicity of β amyloid. The β amyloid-binding characteristics of optimised structural conformations of polyphenols with ascribed neuroprotective actions including punicalagin, myricetin, luteolin and honokiol were determined in silico. Thioflavin T and transmission electron microscopy were used to assess in vitro inhibitory effects of these polyphenols on Aβ1-42 fibril and aggregation formation. Phaeochromocytoma (PC12) cells were exposed to Aβ1-42, alone and in combination with test concentrations of each polyphenol (100 μM) and viability measured using MTT assay. Aβ1-42 evoked a concentration-dependent loss of cell viability in PC12 cells, in which all four polyphenols demonstrated significant inhibition of neurotoxicity. While all compounds variably altered the morphology of Aβ aggregation, the flavonoids luteolin and myricetin and the lignan honokiol all bound in a similar hydrophobic region of the amyloid pentamer and exerted the most pronounced inhibition of Aβ1-42 aggregation.
2.Protective effects of honokiol on ischemia/reperfusion injury of rat ovary: an experimental study.
Yaman Tunc S1, Agacayak E1, Goruk NY2, Icen MS1, Turgut A1, Alabalik U3, Togrul C4, Ekinci C5, Ekinci A6, Gul T1. Drug Des Devel Ther. 2016 Mar 8;10:1077-83. doi: 10.2147/DDDT.S93768. eCollection 2016.
AIM: The purpose of this study was to investigate the protective effect of honokiol on experimental ischemia/reperfusion injury of rat ovary.
3.Protective effect of Honokiol against endometriosis in Rats via attenuating Survivin and Bcl-2: A mechanistic study.
Wang Y1, Jiang LL1, Wu JF1, Liu Z2. Cell Mol Biol (Noisy-le-grand). 2016 Jan 11;62(1):1-5.
Nearly 10-15% of women in the reproductive age were affected by endometriosis and currently facing the unmet need of effective therapeutic interventions for its management. Concerning this, the present study was intended to investigate the effect of Honokiol (HK) for the treatment of endometrial hyperplasia. The rat endometrial model was established and subsequently administered with a numerous dose of HK. The histopathology of tissues was also investigated. Results showed that, HK effectively inhibit the proliferation of rat edometeriotic tissues in a dose dependent manner. In terminal deoxynucleotidyl transferase (TdT) -mediated dUTP biotin nick end labeling (TUNEL) method, HK was able to bring apoptosis in endometrotic cells. Moreover, it also inhibits the mRNA levels of Survivin gene and Bcl-2 (B-cell lymphoma 2) in qPCR and Western blot analysis together with increases the mRNA level of apoptosis promoting factor Bax. These results clearly suggest that, HK was proficient to provoke apoptosis of rat endometriotic cells.
4.Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction.
Huang JS1,2, Yao CJ1,2,3, Chuang SE4, Yeh CT5, Lee LM6, Chen RM1,7, Chao WJ4, Whang-Peng J1,2, Lai GM8,9,10,11. BMC Cancer. 2016 Mar 24;16(1):245. doi: 10.1186/s12885-016-2265-6.
BACKGROUND: Eliminating cancer stem cells (CSCs) has been suggested for prevention of tumor recurrence and metastasis. Honokiol, an active compound of Magnolia officinalis, had been proposed to be a potential candidate drug for cancer treatment. We explored its effects on the elimination of oral CSCs both in vitro and in vivo.

Recommended Products

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code

Copyright © 2024 BOC Sciences. All rights reserved.

cartIcon
Inquiry Basket